Inflammation and myeloperoxidase – The next treatment targets in heart failure?
Authors:
- 6 February 2024
- journal article
- editorial
- Published by Elsevier in International Journal of Cardiology
- Vol. 401, 131834
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and ObesityNew England Journal of Medicine, 2023
- Rationale and Design of ENDEAVOR: A Sequential Phase 2b–3 Randomized Clinical Trial to Evaluate the Effect of Myeloperoxidase Inhibition on Symptoms and Exercise Capacity in Heart Failure with Preserved or Mildly Reduced Ejection FractionEuropean Journal of Heart Failure, 2023
- Myeloperoxidase Inhibition Reverses Biomarker Profiles Associated With Clinical Outcomes in HFpEFJACC: Heart Failure, 2023
- Association between myeloperoxidase and the risks of ischemic stroke, heart failure, and atrial fibrillation: A Mendelian randomization studyNutrition, Metabolism and Cardiovascular Diseases, 2022
- Heart failure with mid-range or mildly reduced ejection fractionNature Reviews Cardiology, 2021
- From Systemic Inflammation to Myocardial FibrosisCirculation Research, 2021
- L-Carnitine supplementation reduces biomarkers of inflammatory and oxidative stress in patients with coronary artery disease: a randomised controlled trialArchives of Physiology and Biochemistry, 2020
- Myeloperoxidase and Related Biomarkers are Suggestive Footprints of Endothelial Microvascular Inflammation in HFpEF PatientsESC Heart Failure, 2020
- Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEFEuropean Heart Journal, 2018
- Microvascular endothelial dysfunction in heart failure with preserved ejection fractionHeart, 2016